S&P 500   4,431.85 (+2.43%)
DOW   34,725.47 (+1.65%)
QQQ   351.80 (+3.14%)
AAPL   170.33 (+6.98%)
MSFT   308.26 (+2.81%)
FB   301.71 (+2.40%)
GOOGL   2,667.02 (+3.37%)
AMZN   2,879.56 (+3.11%)
TSLA   846.35 (+2.08%)
NVDA   228.40 (+4.08%)
BABA   115.23 (+3.08%)
NIO   20.90 (-0.99%)
AMD   105.24 (+2.57%)
CGC   7.27 (+6.13%)
MU   79.27 (+0.70%)
GE   92.10 (+2.45%)
T   25.21 (+4.52%)
F   19.54 (-0.05%)
DIS   138.63 (+2.37%)
AMC   15.06 (+3.72%)
PFE   54.33 (+1.80%)
ACB   3.91 (+3.17%)
BA   190.57 (+0.43%)
S&P 500   4,431.85 (+2.43%)
DOW   34,725.47 (+1.65%)
QQQ   351.80 (+3.14%)
AAPL   170.33 (+6.98%)
MSFT   308.26 (+2.81%)
FB   301.71 (+2.40%)
GOOGL   2,667.02 (+3.37%)
AMZN   2,879.56 (+3.11%)
TSLA   846.35 (+2.08%)
NVDA   228.40 (+4.08%)
BABA   115.23 (+3.08%)
NIO   20.90 (-0.99%)
AMD   105.24 (+2.57%)
CGC   7.27 (+6.13%)
MU   79.27 (+0.70%)
GE   92.10 (+2.45%)
T   25.21 (+4.52%)
F   19.54 (-0.05%)
DIS   138.63 (+2.37%)
AMC   15.06 (+3.72%)
PFE   54.33 (+1.80%)
ACB   3.91 (+3.17%)
BA   190.57 (+0.43%)
S&P 500   4,431.85 (+2.43%)
DOW   34,725.47 (+1.65%)
QQQ   351.80 (+3.14%)
AAPL   170.33 (+6.98%)
MSFT   308.26 (+2.81%)
FB   301.71 (+2.40%)
GOOGL   2,667.02 (+3.37%)
AMZN   2,879.56 (+3.11%)
TSLA   846.35 (+2.08%)
NVDA   228.40 (+4.08%)
BABA   115.23 (+3.08%)
NIO   20.90 (-0.99%)
AMD   105.24 (+2.57%)
CGC   7.27 (+6.13%)
MU   79.27 (+0.70%)
GE   92.10 (+2.45%)
T   25.21 (+4.52%)
F   19.54 (-0.05%)
DIS   138.63 (+2.37%)
AMC   15.06 (+3.72%)
PFE   54.33 (+1.80%)
ACB   3.91 (+3.17%)
BA   190.57 (+0.43%)
S&P 500   4,431.85 (+2.43%)
DOW   34,725.47 (+1.65%)
QQQ   351.80 (+3.14%)
AAPL   170.33 (+6.98%)
MSFT   308.26 (+2.81%)
FB   301.71 (+2.40%)
GOOGL   2,667.02 (+3.37%)
AMZN   2,879.56 (+3.11%)
TSLA   846.35 (+2.08%)
NVDA   228.40 (+4.08%)
BABA   115.23 (+3.08%)
NIO   20.90 (-0.99%)
AMD   105.24 (+2.57%)
CGC   7.27 (+6.13%)
MU   79.27 (+0.70%)
GE   92.10 (+2.45%)
T   25.21 (+4.52%)
F   19.54 (-0.05%)
DIS   138.63 (+2.37%)
AMC   15.06 (+3.72%)
PFE   54.33 (+1.80%)
ACB   3.91 (+3.17%)
BA   190.57 (+0.43%)
NASDAQ:MORF

Morphic Stock Forecast, Price & News

$40.95
+2.69 (+7.03%)
(As of 01/28/2022 04:00 PM ET)
Add
Compare
Today's Range
$37.65
$41.09
50-Day Range
$38.26
$52.02
52-Week Range
$32.56
$93.00
Volume
202,432 shs
Average Volume
194,596 shs
Market Capitalization
$1.51 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.23
30 days | 90 days | 365 days | Advanced Chart
Receive MORF News and Ratings via Email

Sign-up to receive the latest news and ratings for Morphic and its competitors with MarketBeat's FREE daily newsletter.


Morphic logo

About Morphic

Morphic Holding, Inc. operates as a biopharmaceutical company, which engages in the research and development of oral small-molecule integrin therapeutics. It operates a Morphic integrin technology platform, MInT platform, to create a broad pipeline of programs across a variety of therapeutic areas. The company was founded by Timothy A. Springer in August 2014 and is headquartered in Waltham, MA.

Headlines

Morphic (NASDAQ:MORF) Shares Gap Down to $41.15
January 20, 2022 |  americanbankingnews.com
Morphic (NASDAQ:MORF) Shares Up 3.6%
January 14, 2022 |  americanbankingnews.com
Morphic Holding Becomes Oversold (MORF) - Nasdaq
November 29, 2021 |  nasdaq.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MORF
Fax
N/A
Employees
89
Year Founded
N/A

Sales & Book Value

Annual Sales
$44.94 million
Book Value
$4.66 per share

Profitability

Net Income
$-45 million
Net Margins
-569.40%
Pretax Margin
-570.28%

Debt

Price-To-Earnings

Miscellaneous

Free Float
25,356,000
Market Cap
$1.51 billion
Optionable
Not Optionable

Company Calendar

Last Earnings
11/04/2021
Today
1/28/2022
Next Earnings (Estimated)
3/07/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.36 out of 5 stars

Medical Sector

234th out of 1,417 stocks

Pharmaceutical Preparations Industry

100th out of 683 stocks

Analyst Opinion: 3.5Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 4.2Valuation: 0.0 5 -4 -3 -2 -1 -












Morphic (NASDAQ:MORF) Frequently Asked Questions

Is Morphic a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Morphic in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Morphic stock.
View analyst ratings for Morphic
or view top-rated stocks.

How has Morphic's stock price been impacted by Coronavirus?

Morphic's stock was trading at $14.41 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, MORF shares have increased by 184.2% and is now trading at $40.95.
View which stocks have been most impacted by COVID-19
.

Are investors shorting Morphic?

Morphic saw a increase in short interest during the month of December. As of December 15th, there was short interest totaling 1,110,000 shares, an increase of 25.8% from the November 30th total of 882,100 shares. Based on an average daily trading volume, of 152,300 shares, the short-interest ratio is presently 7.3 days. Currently, 5.1% of the shares of the company are short sold.
View Morphic's Short Interest
.

When is Morphic's next earnings date?

Morphic is scheduled to release its next quarterly earnings announcement on Monday, March 7th 2022.
View our earnings forecast for Morphic
.

How were Morphic's earnings last quarter?

Morphic Holding, Inc. (NASDAQ:MORF) posted its quarterly earnings results on Thursday, November, 4th. The company reported ($0.69) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.73) by $0.04. The company had revenue of $3.10 million for the quarter, compared to the consensus estimate of $5.19 million. Morphic had a negative net margin of 569.40% and a negative trailing twelve-month return on equity of 30.32%. Morphic's revenue for the quarter was down 88.0% on a year-over-year basis.
View Morphic's earnings history
.

What price target have analysts set for MORF?

3 equities research analysts have issued 1 year target prices for Morphic's shares. Their forecasts range from $50.00 to $102.00. On average, they anticipate Morphic's stock price to reach $77.67 in the next twelve months. This suggests a possible upside of 89.7% from the stock's current price.
View analysts' price targets for Morphic
or view top-rated stocks among Wall Street analysts.

Who are Morphic's key executives?

Morphic's management team includes the following people:

What other stocks do shareholders of Morphic own?

When did Morphic IPO?

(MORF) raised $75 million in an IPO on Thursday, June 27th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Jefferies, Cowen, BMO Capital Markets and Wells Fargo Securities acted as the underwriters for the IPO.

What is Morphic's stock symbol?

Morphic trades on the NASDAQ under the ticker symbol "MORF."

Who are Morphic's major shareholders?

Morphic's stock is owned by many different institutional and retail investors. Top institutional investors include Allspring Global Investments Holdings LLC (0.03%). Company insiders that own Morphic stock include Alexey Lugovskoy, Amir Nashat, Bruce Rogers, Fund V Gp LP Omega, Fund V LP Omega, Marc Schegerin, Peter Linde, Praveen P Tipirneni, Robert E Farrell Jr, Robert E Farrell, Jr, Timothy A Springer, Timothy A Springer and William Devaul.
View institutional ownership trends for Morphic
.

Which institutional investors are buying Morphic stock?

MORF stock was purchased by a variety of institutional investors in the last quarter, including Allspring Global Investments Holdings LLC.
View insider buying and selling activity for Morphic
or or view top insider-buying stocks.

How do I buy shares of Morphic?

Shares of MORF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Morphic's stock price today?

One share of MORF stock can currently be purchased for approximately $40.95.

How much money does Morphic make?

Morphic has a market capitalization of $1.51 billion and generates $44.94 million in revenue each year. The company earns $-45 million in net income (profit) each year or ($2.66) on an earnings per share basis.

How many employees does Morphic have?

Morphic employs 89 workers across the globe.

What is Morphic's official website?

The official website for Morphic is www.morphictx.com.

Where are Morphic's headquarters?

Morphic is headquartered at 35 Gatehouse Drive A2, Waltham MA, 02451.

How can I contact Morphic?

Morphic's mailing address is 35 Gatehouse Drive A2, Waltham MA, 02451. The company can be reached via phone at (781) 996-0955.


This page was last updated on 1/28/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.